Skip to main
TNDM
TNDM logo

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 27%
Sell 3%
Strong Sell 3%

Bulls say

Tandem Diabetes Care is positioned for substantial long-term growth, evidenced by a 20.6% year-over-year increase in top-line revenue, reaching $252.4 million, which surpassed consensus estimates. The expansion of its product pipeline, including FDA clearance for Type 2 diabetes devices, has more than doubled its addressable market in the U.S., enhancing its growth prospects. Additionally, the company's strong customer satisfaction ratings have resulted in high retention rates and consistent double-digit revenue growth expectations, driven by a combination of pump sales and increasing demand for disposable infusion sets.

Bears say

Tandem Diabetes Care has experienced significant operating losses since its inception and has not demonstrated sustainable profitability, raising concerns about its financial viability. The company provided underwhelming 2025 guidance reflecting weaker-than-expected trends, competition, and potential reimbursement issues, leading to a substantial decline in stock value. Gross margins of 50.7% fell short of consensus estimates, compounding investor apprehension about the company's ability to improve financial performance amidst global economic uncertainties.

TNDM has been analyzed by 30 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 27% suggest Holding, 3% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 30 analysts, TNDM has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.